CARDIORENAL PROTECTION: POTENTIAL OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF TYPE 2 DIABETES

Descargar Publicación
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force